Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

ClinicalTrials.gov ID: NCT00940602

Public ClinicalTrials.gov record NCT00940602. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was conducted in 17 countries, started in 2010 and ended in 2018.

Study identification

NCT ID
NCT00940602
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
225 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 21, 2010
Primary completion
Feb 26, 2018
Completion
Feb 26, 2018
Last update posted
Nov 22, 2020

2010 – 2018

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Pacific Cancer Medical Center, Inc. PAC Center Anaheim California 92801
Rocky Mountain Cancer Centers RMCC Greenwood Village Colorado
Willis-Knighton Cancer Center Dept of Onc Shreveport Louisiana 71103
Henry Ford Hospital Henry Ford Detroit Michigan 48202
Midwest Cancer Care Physicians MMCC Kansas City Missouri 64131
Mercy Medical Research Institute SC Manchester Missouri 63021
Glacier View Research Institute - Cancer SC Kalispell Montana 59901
Hackensack University Medical Center Department of Research Hackensack New Jersey 07601
University of Texas MD Anderson Cancer Center Dept of MD Anderson (16) Houston Texas 77030
Cancer Care Centers of South Texas HOAST CCC of So.TX- MedicalCenter(2) San Antonio Texas 78229
Swedish Cancer Institute Ballard Campus Seattle Washington 98107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00940602, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2020 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00940602 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →